cobenfy karxt news - Search News

FDA Approves 1st New Schizophrenia Drug in Decades

FDA Approves the First New Type of Schizophrenia Drug in Decades

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle movement, and sedation — that can cause patients to discontinue treatment.

Gizmodo · 1h

FDA Approves Potentially Groundbreaking Schizophrenia Drug

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.

Firstpost · 7h

Why approval of KarXT, the first new drug for schizophrenia in decades, is a big deal

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as KarXT or Cobenfy. It comes without common side effects such as weight gain a

Public Radio Tulsa12m

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...

FiercePharma21h

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

The American Journal of Managed Care5h

First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...

C&EN21h

FDA approves Cobenfy, a first-in-class schizophrenia drug

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics